 |
5 Diseases |  |
0 Trials |
|
0 Trials |  |
16 News |  |
- | Laviv (autologous fibroblast cell therapy system) / Paragon Biosci, Precigen
Trial completion: Controlled Study to Evaluate the Safety and Efficacy of Azficel-T for Vocal Fold Scarring and Age-Related Dysphonia (clinicaltrials.gov) - Feb 1, 2017
P2, N=20, Completed, Sponsor: Fibrocell Technologies, Inc.
Active, not recruiting --> Completed
- Laviv (autologous fibroblast cell therapy system) / Paragon Biosci, Precigen
Enrollment change, Trial termination: Pilot Study of Azficel-T for the Treatment of Restrictive Burn Scars (clinicaltrials.gov) - Jul 11, 2016
P2, N=3, Terminated, Sponsor: Fibrocell Technologies, Inc.
Active, not recruiting --> Completed N=21 --> 3 | Active, not recruiting --> Terminated; unable to enroll
- Laviv (autologous fibroblast cell therapy system) / Paragon Biosci, Precigen
Trial primary completion date: Controlled Study to Evaluate the Safety and Efficacy of Azficel-T for Vocal Fold Scarring and Age-Related Dysphonia (clinicaltrials.gov) - Jan 28, 2016
P2, N=20, Active, not recruiting, Sponsor: Fibrocell Technologies, Inc.
N=21 --> 3 | Active, not recruiting --> Terminated; unable to enroll Trial primary completion date: Dec 2015 --> May 2016
- Laviv (autologous fibroblast cell therapy system) / Paragon Biosci, Precigen
Trial primary completion date: Pilot Study of Azficel-T for the Treatment of Restrictive Burn Scars (clinicaltrials.gov) - Jan 27, 2016
P2, N=21, Active, not recruiting, Sponsor: Fibrocell Technologies, Inc.
Trial primary completion date: Dec 2015 --> May 2016 Trial primary completion date: Oct 2015 --> May 2016
- | Laviv (autologous fibroblast cell therapy system) / Paragon Biosci, Precigen
Enrollment closed: Controlled Study to Evaluate the Safety and Efficacy of Azficel-T for Vocal Fold Scarring and Age-Related Dysphonia (clinicaltrials.gov) - Aug 6, 2015
P2, N=20, Active, not recruiting, Sponsor: Fibrocell Technologies, Inc.
Trial primary completion date: Oct 2015 --> May 2016 Recruiting --> Active, not recruiting
- Laviv (autologous fibroblast cell therapy system) / Paragon Biosci, Precigen
Trial primary completion date: Controlled Study to Evaluate the Safety and Efficacy of Azficel-T for Vocal Fold Scarring and Age-Related Dysphonia (clinicaltrials.gov) - Jan 22, 2015
P2, N=20, Recruiting, Sponsor: Fibrocell Technologies, Inc.
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2014 --> Dec 2015
- | Laviv (autologous fibroblast cell therapy system) / Paragon Biosci, Precigen
Enrollment closed, Trial primary completion date: Pilot Study of Azficel-T for the Treatment of Restrictive Burn Scars (clinicaltrials.gov) - Jan 22, 2015
P2, N=21, Active, not recruiting, Sponsor: Fibrocell Technologies, Inc.
Trial primary completion date: Dec 2014 --> Dec 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2014 --> Oct 2015
- | Laviv (autologous fibroblast cell therapy system) / Paragon Biosci, Precigen
New P2 trial: Controlled Study to Evaluate the Safety and Efficacy of Azficel-T for Vocal Fold Scarring and Age-Related Dysphonia (clinicaltrials.gov) - Apr 21, 2014
P2, N=20, Recruiting, Sponsor: Fibrocell Technologies, Inc.
- | Laviv (autologous fibroblast cell therapy system) / Paragon Biosci, Precigen
Enrollment open: Controlled Study to Evaluate the Safety and Efficacy of Azficel-T for Vocal Fold Scarring and Age-Related Dysphonia (clinicaltrials.gov) - Apr 20, 2014
P2, N=20, Recruiting, Sponsor: Fibrocell Technologies, Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2014 --> Oct 2015 Not yet recruiting --> Recruiting
- | Laviv (autologous fibroblast cell therapy system) / Paragon Biosci, Precigen
New P2 trial: Pilot Study of Azficel-T for the Treatment of Restrictive Burn Scars (clinicaltrials.gov) - May 19, 2013
P2, N=21, Recruiting, Sponsor: Fibrocell Technologies, Inc.
- Laviv (autologous fibroblast cell therapy system) / Paragon Biosci, Precigen
Trial withdrawal: Pilot Safety and Efficacy Study of Isolagen Therapy in Treatment of Restrictive Burn Scars (clinicaltrials.gov) - Feb 7, 2012
P2, N=0, Withdrawn, Sponsor: Fibrocell Technologies, Inc.
Not yet recruiting --> Recruiting Suspended --> Withdrawn
- Laviv (autologous fibroblast cell therapy system) / Paragon Biosci, Precigen
Enrollment change: Pilot Safety and Efficacy Study of Isolagen Therapy in Treatment of Restrictive Burn Scars (clinicaltrials.gov) - Feb 7, 2012
P2, N=0, Withdrawn, Sponsor: Fibrocell Technologies, Inc.
Suspended --> Withdrawn N=30 --> 0